Table Info

Drug	Model and mechanisms	Author	Reference
TMP195	HDAC9 inhibition (hyperlipidemic mice)	Asare et al. (2020)	[163]
RGFP966	HDAC3 inhibition (ApoE^-/- mice)	Chen et al. (2021)	[164]
MC1568	HDAC9 inhibition (ex vivo genetic knockout HDAC9 endothelial cells)	Lecce et al.	[165]
Sodium valproate	HDAC9 inhibition (human patients)	Brookes et al. (2018)	[166]

Declarations

Acknowledgments

We thank all members of the Department of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, and the National Natural Sciences Foundation of China for their support.

Author contributions

SCW: Writing—original draft. XMJ: Conceptualization, Investigation, Writing—review & editing. MX: Conceptualization, Investigation, Writing—review & editing, Funding acquisition.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This work is supported by the National Natural Science Foundation of China [82373870]. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Cardiovascular diseases (cvds) [Internet]. WHO; c2024 [cited 2023 Jun 13]. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)

Shah SR, Abbasi Z, Fatima M, Ochani RK, Shahnawaz W, Khan MA, et al. Canakinumab and cardiovascular outcomes: results of the CANTOS trial. J Community Hosp Intern Med Perspect. 2018;8:21–2. [DOI] [PubMed] [PMC]

Ridker PM, Devalaraja M, Baeres FMM, Engelmann MDM, Hovingh GK, Ivkovic M, et al.; RESCUE Investigators. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397:2060–9. [DOI] [PubMed]

Tardif J, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381:2497–505. [DOI] [PubMed]

Ridker PM, Rane M. Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circ Res. 2021;128:1728–46. [DOI] [PubMed]

Minamino T, Miyauchi H, Yoshida T, Tateno K, Kunieda T, Komuro I. Vascular cell senescence and vascular aging. J Mol Cell Cardiol. 2004;36:175–83. [DOI] [PubMed]

Wang JC, Bennett M. Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res. 2012;111:245–59. [DOI] [PubMed]

Golledge J. Update on the pathophysiology and medical treatment of peripheral artery disease. Nat Rev Cardiol. 2022;19:456–74. [DOI] [PubMed]

O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007;50:1–13. [DOI] [PubMed]

10.

Zhang W, Hui R, Yang S. Telomeres, cardiovascular aging, and potential intervention for cellular senescence. Sci China Life Sci. 2014;57:858–62. [DOI] [PubMed]

11.

Ungvari Z, Tarantini S, Donato AJ, Galvan V, Csiszar A. Mechanisms of Vascular Aging. Circ Res. 2018;123:849–67. [DOI] [PubMed] [PMC]

12.

Abdellatif M, Rainer PP, Sedej S, Kroemer G. Hallmarks of cardiovascular ageing. Nat Rev Cardiol. 2023;20:754–77. [DOI] [PubMed]

13.

López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186:243–78. [DOI] [PubMed]

14.

Bu L, Yuan H, Xie L, Guo M, Liao D, Zheng X. New Dawn for Atherosclerosis: Vascular Endothelial Cell Senescence and Death. Int J Mol Sci. 2023;24:15160. [DOI] [PubMed] [PMC]

15.

Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 2001;104:503–16. [DOI] [PubMed]

16.

Björkegren JLM, Lusis AJ. Atherosclerosis: Recent developments. Cell. 2022;185:1630–45. [DOI] [PubMed] [PMC]

17.

Park YM. CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med. 2014;46:e99. [DOI] [PubMed] [PMC]

18.

Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci. 2013;70:2859–72. [DOI] [PubMed] [PMC]

19.

Hamczyk MR, Villa-Bellosta R, Quesada V, Gonzalo P, Vidak S, Nevado RM, et al. Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells. EMBO Mol Med. 2019;11:e9736. [DOI] [PubMed] [PMC]

20.

Ulleryd MA, Prahl U, Börsbo J, Schmidt C, Nilsson S, Bergström G, et al. The association between autonomic dysfunction, inflammation and atherosclerosis in men under investigation for carotid plaques. PLoS One. 2017;12:e0174974. [DOI] [PubMed] [PMC]

21.

Saigusa R, Winkels H, Ley K. T cell subsets and functions in atherosclerosis. Nat Rev Cardiol. 2020;17:387–401. [DOI] [PubMed] [PMC]

22.

Combadière C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C^hi and Ly6C^lomonocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008;117:1649–57. [DOI] [PubMed]

23.

Chen J, Xiang X, Nie L, Guo X, Zhang F, Wen C, et al. The emerging role of Th1 cells in atherosclerosis and its implications for therapy. Front Immunol. 2023;13:1079668. [DOI] [PubMed] [PMC]

24.

Tse K, Tse H, Sidney J, Sette A, Ley K. T cells in atherosclerosis. Int Immunol. 2013;25:615–22. [DOI] [PubMed] [PMC]

25.

Hinkley H, Counts DA, VonCanon E, Lacy M. T Cells in Atherosclerosis: Key Players in the Pathogenesis of Vascular Disease. Cells. 2023;12:2152. [DOI] [PubMed] [PMC]

26.

Song X, Song Y, Ma Q, Fang K, Chang X. M1-Type Macrophages Secrete TNF-α to Stimulate Vascular Calcification by Upregulating CA1 and CA2 Expression in VSMCs. J Inflamm Res. 2023;16:3019–32. [DOI] [PubMed] [PMC]

27.

Tabas I, Bornfeldt KE. Intracellular and Intercellular Aspects of Macrophage Immunometabolism in Atherosclerosis. Circ Res. 2020;126:1209–27. [DOI] [PubMed] [PMC]

28.

Crowley SD, Rudemiller NP. Immunologic Effects of the Renin-Angiotensin System. J Am Soc Nephrol. 2017;28:1350–61. [DOI] [PubMed] [PMC]

29.

Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000;93:65–77. [DOI] [PubMed]

30.

Marques PE, Nyegaard S, Collins RF, Troise F, Freeman SA, Trimble WS, et al. Multimerization and Retention of the Scavenger Receptor SR-B1 in the Plasma Membrane. Dev Cell. 2019;50:283–95.e5. [DOI] [PubMed]

31.

Koutsouki E, Beeching CA, Slater SC, Blaschuk OW, Sala-Newby GB, George SJ. N-cadherin-dependent cell-cell contacts promote human saphenous vein smooth muscle cell survival. Arterioscler Thromb Vasc Biol. 2005;25:982–8. [DOI] [PubMed]

32.

Lyon CA, Johnson JL, White S, Sala-Newby GB, George SJ. EC4, a truncation of soluble N-cadherin, reduces vascular smooth muscle cell apoptosis and markers of atherosclerotic plaque instability. Mol Ther Methods Clin Dev. 2014;1:14004. [DOI] [PubMed] [PMC]

33.

Patel P, Rai V, Agrawal DK. Role of oncostatin-M in ECM remodeling and plaque vulnerability. Mol Cell Biochem. 2023;478:2451–60. [DOI] [PubMed] [PMC]

34.

Yu EPK, Bennett MR. Mitochondrial DNA damage and atherosclerosis. Trends Endocrinol Metab. 2014;25:481–7. [DOI] [PubMed]

35.

Ricottini E, Madonna R, Grieco D, Zoccoli A, Stampachiacchiere B, Patti G, et al. Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study). Am J Cardiol. 2016;117:165–71. [DOI] [PubMed]

36.

Pan M, Li K, Lin S, Hung W. Connecting the Dots: From DNA Damage and Repair to Aging. Int J Mol Sci. 2016;17:685. [DOI] [PubMed] [PMC]

37.

Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29:946–60. [DOI] [PubMed] [PMC]

38.

Yu E, Calvert PA, Mercer JR, Harrison J, Baker L, Figg NL, et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans. Circulation. 2013;128:702–12. [DOI] [PubMed]

39.

Miyamoto S. Nuclear initiated NF-κB signaling: NEMO and ATM take center stage. Cell Res. 2011;21:116–30. [DOI] [PubMed] [PMC]

40.

Casella G, Tsitsipatis D, Abdelmohsen K, Gorospe M. mRNA methylation in cell senescence. Wiley Interdiscip Rev RNA. 2019;10:e1547. [DOI] [PubMed] [PMC]

41.

Lee JW, Ong EBB. Genomic Instability and Cellular Senescence: Lessons From the Budding Yeast. Front Cell Dev Biol. 2021;8:619126. [DOI] [PubMed] [PMC]

42.

Vijg J, Suh Y. Genome instability and aging. Annu Rev Physiol. 2013;75:645–68. [DOI] [PubMed]

43.

Tang MLF, Khan MKN, Croxford JL, Tan KW, Angeli V, Gasser S. The DNA damage response induces antigen presenting cell-like functions in fibroblasts. Eur J Immunol. 2014;44:1108–18. [DOI] [PubMed]

44.

Ewing MM, Karper JC, Abdul S, Jong RCMd, Peters HAB, Vries MRd, et al. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol. 2013;168:1965–74. [DOI] [PubMed]

45.

Poels K, Leent MMTv, Reiche ME, Kusters PJH, Huveneers S, Winther MPJd, et al. Antibody-Mediated Inhibition of CTLA4 Aggravates Atherosclerotic Plaque Inflammation and Progression in Hyperlipidemic Mice. Cells. 2020;9:1987. [DOI] [PubMed] [PMC]

46.

Wu Z, Zhang W, Song M, Wang W, Wei G, Li W, et al. Differential stem cell aging kinetics in Hutchinson-Gilford progeria syndrome and Werner syndrome. Protein Cell. 2018;9:333–50. [DOI] [PubMed] [PMC]

47.

Yang K, Hou R, Zhao J, Wang X, Wei J, Pan X, et al. Lifestyle effects on aging and CVD: A spotlight on the nutrient-sensing network. Ageing Res Rev. 2023;92:102121. [DOI] [PubMed]

48.

Cervelli T, Borghini A, Galli A, Andreassi MG. DNA damage and repair in atherosclerosis: current insights and future perspectives. Int J Mol Sci. 2012;13:16929–44. [DOI] [PubMed] [PMC]

49.

Ballinger SW, Patterson C, Knight-Lozano CA, Burow DL, Conklin CA, Hu Z, et al. Mitochondrial integrity and function in atherogenesis. Circulation. 2002;106:544–9. [DOI] [PubMed]

50.

Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021;18:58–68. [DOI] [PubMed] [PMC]

51.

Zhang Y, Weng J, Huan L, Sheng S, Xu F. Mitophagy in atherosclerosis: from mechanism to therapy. Front Immunol. 2023;14:1165507. [DOI] [PubMed] [PMC]

52.

Mercer JR, Cheng K, Figg N, Gorenne I, Mahmoudi M, Griffin J, et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res. 2010;107:1021–31. [DOI] [PubMed] [PMC]

53.

Peng W, Cai G, Xia Y, Chen J, Wu P, Wang Z, et al. Mitochondrial Dysfunction in Atherosclerosis. DNA Cell Biol. 2019;38:597–606. [DOI] [PubMed]

54.

Hoffmann J, Richardson G, Haendeler J, Altschmied J, Andrés V, Spyridopoulos I. Telomerase as a Therapeutic Target in Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2021;41:1047–61. [DOI] [PubMed]

55.

Brouilette SW, Moore JS, McMahon AD, Thompson JR, Ford I, Shepherd J, et al.; West of Scotland Coronary Prevention Study Group. Telomere length, risk of coronary heart disease, and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet. 2007;369:107–14. [DOI] [PubMed]

56.

Yegorov YE, Poznyak AV, Nikiforov NG, Starodubova AV, Orekhov AN. Role of Telomeres Shortening in Atherogenesis: An Overview. Cells. 2021;10:395. [DOI] [PubMed] [PMC]

57.

Matthews C, Gorenne I, Scott S, Figg N, Kirkpatrick P, Ritchie A, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res. 2006;99:156–64. [DOI] [PubMed]

58.

Bloom SI, Liu Y, Tucker JR, Islam MT, Machin DR, Abdeahad H, et al. Endothelial cell telomere dysfunction induces senescence and results in vascular and metabolic impairments. Aging Cell. 2023;22:e13875. [DOI] [PubMed] [PMC]

59.

Stevanovic M, Lazic A, Schwirtlich M, Ninkovic DS. The Role of SOX Transcription Factors in Ageing and Age-Related Diseases. Int J Mol Sci. 2023;24:851. [DOI] [PubMed] [PMC]

60.

Ramunas J, Yakubov E, Brady JJ, Corbel SY, Holbrook C, Brandt M, et al. Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells. FASEB J. 2015;29:1930–9. [DOI] [PubMed] [PMC]

61.

Yeh J, Lin M, Wang C. Telomeres as Therapeutic Targets in Heart Disease. JACC Basic Transl Sci. 2019;4:855–65. [DOI] [PubMed] [PMC]

62.

Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med. 2017;377:111–21. [DOI] [PubMed] [PMC]

63.

Fidler TP, Xue C, Yalcinkaya M, Hardaway B, Abramowicz S, Xiao T, et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 2021;592:296–301. [DOI] [PubMed] [PMC]

64.

Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21:20–7. [DOI] [PubMed]

65.

Ekholm M, Kahan T. The Impact of the Renin-Angiotensin-Aldosterone System on Inflammation, Coagulation, and Atherothrombotic Complications, and to Aggravated COVID-19. Front Pharmacol. 2021;12:640185. [DOI] [PubMed] [PMC]

66.

Wu L, Chen K, Xiao J, Xin J, Zhang L, Li X, et al. Angiotensin II induces RAW264.7 macrophage polarization to the M1‑type through the connexin 43/NF‑κB pathway. Mol Med Rep. 2020;21:2103–12. [DOI] [PubMed] [PMC]

67.

Wang Y, Tikellis C, Thomas MC, Golledge J. Angiotensin converting enzyme 2 and atherosclerosis. Atherosclerosis. 2013;226:3–8. [DOI] [PubMed]

68.

Pan H, Huang W, Wang Z, Ren F, Luo L, Zhou J, et al. The ACE2-Ang-(1‑7)-Mas Axis Modulates M1/M2 Macrophage Polarization to Relieve CLP-Induced Inflammation via TLR4-Mediated NF-кb and MAPK Pathways. J Inflamm Res. 2021;14:2045–60. [DOI] [PubMed] [PMC]

69.

Diz DI, Varagic J, Groban L. Aging and the brain renin-angiotensin system: relevance to age-related decline in cardiac function. Future Cardiol. 2008;4:237–45. [DOI] [PubMed] [PMC]

70.

Yoon HE, Kim EN, Kim MY, Lim JH, Jang I, Ban TH, et al. Age-Associated Changes in the Vascular Renin-Angiotensin System in Mice. Oxid Med Cell Longev. 2016;2016:6731093. [DOI] [PubMed] [PMC]

71.

Grainger DJ. Transforming growth factor β and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004;24:399–404. [DOI] [PubMed]

72.

Tominaga K, Suzuki HI. TGF-β Signaling in Cellular Senescence and Aging-Related Pathology. Int J Mol Sci. 2019;20:5002. [DOI] [PubMed] [PMC]

73.

Fleenor BS, Marshall KD, Durrant JR, Lesniewski LA, Seals DR. Arterial stiffening with ageing is associated with transforming growth factor-β1-related changes in adventitial collagen: reversal by aerobic exercise. J Physiol. 2010;588:3971–82. [DOI] [PubMed] [PMC]

74.

Wang B, Omar A, Angelovska T, Drobic V, Rattan SG, Jones SC, et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Physiol Heart Circ Physiol. 2007;293:H1282–90. [DOI] [PubMed]

75.

Toma I, McCaffrey TA. Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Cell Tissue Res. 2012;347:155–75. [DOI] [PubMed] [PMC]

76.

Chen P, Qin L, Li G, Wang Z, Dahlman JE, Malagon-Lopez J, et al. Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis. Nat Metab. 2019;1:912–26. [DOI] [PubMed] [PMC]

77.

Macvanin M, Gluvic Z, Radovanovic J, Essack M, Gao X, Isenovic ER. New insights on the cardiovascular effects of IGF-1. Front Endocrinol (Lausanne). 2023;14:1142644. [DOI] [PubMed] [PMC]

78.

Abdellatif M, Trummer-Herbst V, Heberle AM, Humnig A, Pendl T, Durand S, et al. Fine-Tuning Cardiac Insulin-Like Growth Factor 1 Receptor Signaling to Promote Health and Longevity. Circulation. 2022;145:1853–66. [DOI] [PubMed] [PMC]

79.

Luo X, Jiang X, Li J, Bai Y, Li Z, Wei P, et al. Insulin-like growth factor-1 attenuates oxidative stress-induced hepatocyte premature senescence in liver fibrogenesis via regulating nuclear p53-progerin interaction. Cell Death Dis. 2019;10:451. [DOI] [PubMed] [PMC]

80.

Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LØ. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol. 2009;160:25–31. [DOI] [PubMed]

81.

Wang Y, Anesi J, Maier MC, Myers MA, Oqueli E, Sobey CG, et al. Sympathetic Nervous System and Atherosclerosis. Int J Mol Sci. 2023;24:13132. [DOI] [PubMed] [PMC]

82.

Kawachi S, Takeda N, Sasaki A, Kokubo Y, Takami K, Sarui H, et al. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:617–21. [DOI] [PubMed]

83.

Harrington SC, Simari RD, Conover CA. Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet. Circ Res. 2007;100:1696–702. [DOI] [PubMed]

84.

Zhao Y, Qian Y, Sun Z, Shen X, Cai Y, Li L, et al. Role of PI3K in the Progression and Regression of Atherosclerosis. Front Pharmacol. 2021;12:632378. [DOI] [PubMed] [PMC]

85.

Abdellatif M, Eisenberg T, Heberle AM, Thedieck K, Kroemer G, Sedej S. Cardiac PI3K p110α attenuation delays aging and extends lifespan. Cell Stress. 2022;6:72–5. [DOI] [PubMed] [PMC]

86.

Zhao Y, Liu Y. Longevity Factor FOXO3: A Key Regulator in Aging-Related Vascular Diseases. Front Cardiovasc Med. 2021;8:778674. [DOI] [PubMed] [PMC]

87.

Barthelemy J, Pichot V, Hupin D, Berger M, Celle S, Mouhli L, et al. Targeting autonomic nervous system as a biomarker of well-ageing in the prevention of stroke. Front Aging Neurosci. 2022;14:969352. [DOI] [PubMed] [PMC]

88.

Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J Physiol. 2000;528:407–17. [DOI] [PubMed] [PMC]

89.

Wang Y, Nguyen DT, Anesi J, Alramahi A, Witting PK, Chai Z, et al. Moxonidine Increases Uptake of Oxidised Low-Density Lipoprotein in Cultured Vascular Smooth Muscle Cells and Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice. Int J Mol Sci. 2023;24:3857. [DOI] [PubMed] [PMC]

90.

Shi S, Li Y, Guo Y, Wang Z. Effect of beta-3 adrenoceptor stimulation on the levels of ApoA-I, PPARα, and PPARγ in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2014;64:407–11. [DOI] [PubMed]

91.

Yao Y, Yang D, Han Y, Wang W, Wang N, Yang J, et al. Dopamine D₁-Like Receptors Suppress the Proliferation of Macrophages Induced by Ox-LDL. Cell Physiol Biochem. 2016;38:415–26. [DOI] [PubMed]

92.

Manzella N, Santin Y, Maggiorani D, Martini H, Douin-Echinard V, Passos JF, et al. Monoamine oxidase-A is a novel driver of stress-induced premature senescence through inhibition of parkin-mediated mitophagy. Aging Cell. 2018;17:e12811. [DOI] [PubMed] [PMC]

93.

Wang Z, Li Y, Guo Y. β₃-Adrenoceptor activation attenuates atherosclerotic plaque formation in ApoE^−/− mice through lowering blood lipids and glucose. Acta Pharmacol Sin. 2013;34:1156–63. [DOI] [PubMed] [PMC]

94.

Li Z, Li Q, Wang L, Li C, Xu M, Duan Y, et al. Targeting mitochondria-inflammation circle by renal denervation reduces atheroprone endothelial phenotypes and atherosclerosis. Redox Biol. 2021;47:102156. [DOI] [PubMed] [PMC]

95.

Santanam N, Thornhill BA, Lau JK, Crabtree CM, Cook CR, Brown KC, et al. Nicotinic acetylcholine receptor signaling in atherogenesis. Atherosclerosis. 2012;225:264–73. [DOI] [PubMed]

96.

Hewing B, Ludwig A, Dan C, Pötzsch M, Hannemann C, Petry A, et al. Immunoproteasome subunit ß5i/LMP7-deficiency in atherosclerosis. Sci Rep. 2017;7:13342. [DOI] [PubMed] [PMC]

97.

Ask TF, Lugo RG, Sütterlin S. The Neuro-Immuno-Senescence Integrative Model (NISIM) on the Negative Association Between Parasympathetic Activity and Cellular Senescence. Front Neurosci. 2018;12:726. [DOI] [PubMed] [PMC]

98.

Wang K, Liu H, Hu Q, Wang L, Liu J, Zheng Z, et al. Epigenetic regulation of aging: implications for interventions of aging and diseases. Signal Transduct Target Ther. 2022;7:374. [DOI] [PubMed] [PMC]

99.

Sánchez-Cabo F, Fuster V, Silla-Castro JC, González G, Lorenzo-Vivas E, Alvarez R, et al. Subclinical atherosclerosis and accelerated epigenetic age mediated by inflammation: a multi-omics study. Eur Heart J. 2023;44:2698–709. [DOI] [PubMed] [PMC]

100.

Hiltunen MO, Turunen MP, Häkkinen TP, Rutanen J, Hedman M, Mäkinen K, et al. DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vasc Med. 2002;7:5–11. [DOI] [PubMed]

101.

Jia L, Zhu L, Wang JZ, Wang XJ, Chen JZ, Song L, et al. Methylation of FOXP3 in regulatory T cells is related to the severity of coronary artery disease. Atherosclerosis. 2013;228:346–52. [DOI] [PubMed]

102.

Valencia-Morales MdP, Zaina S, Heyn H, Carmona FJ, Varol N, Sayols S, et al. The DNA methylation drift of the atherosclerotic aorta increases with lesion progression. BMC Med Genomics. 2015;8:7. [DOI] [PubMed] [PMC]

103.

Jiang Y, Jiménez JM, Ou K, McCormick ME, Zhang L, Davies PF. Hemodynamic disturbed flow induces differential DNA methylation of endothelial Kruppel-Like Factor 4 promoter in vitro and in vivo. Circ Res. 2014;115:32–43. [DOI] [PubMed] [PMC]

104.

Guay S, Brisson D, Munger J, Lamarche B, Gaudet D, Bouchard L. ABCA1 gene promoter DNA methylation is associated with HDL particle profile and coronary artery disease in familial hypercholesterolemia. Epigenetics. 2012;7:464–72. [DOI] [PubMed]

105.

Zhang Y, Mei J, Li J, Zhang Y, Zhou Q, Xu F. DNA Methylation in Atherosclerosis: A New Perspective. Evid Based Complement Alternat Med. 2021;2021:6623657. [DOI] [PubMed] [PMC]

106.

Lacey M, Baribault C, Ehrlich KC, Ehrlich M. Atherosclerosis-associated differentially methylated regions can reflect the disease phenotype and are often at enhancers. Atherosclerosis. 2019;280:183–91. [DOI] [PubMed] [PMC]

107.

Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015;525:389–93. [DOI] [PubMed] [PMC]

108.

Liu Y, Peng W, Qu K, Lin X, Zeng Z, Chen J, et al. TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis. DNA Cell Biol. 2018;37:517–23. [DOI] [PubMed] [PMC]

109.

Jiang L, Yu X, Chen J, Hu M, Zhang Y, Lin H, et al. Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis. Aging Dis. 2022;13:773–86. [DOI] [PubMed] [PMC]

110.

Das S, Natarajan R. HDAC9: An Inflammatory Link in Atherosclerosis. Circ Res. 2020;127:824–6. [DOI] [PubMed] [PMC]

111.

Zheng X, Zhou T, Wang X, Tong X, Ding J. Histone deacetylases and atherosclerosis. Atherosclerosis. 2015;240:355–66. [DOI] [PubMed]

112.

Wang L, Ahn YJ, Asmis R. Inhibition of myeloid HDAC2 upregulates glutaredoxin 1 expression, improves protein thiol redox state and protects against high-calorie diet-induced monocyte dysfunction and atherosclerosis. Atherosclerosis. 2021;328:23–32. [DOI] [PubMed]

113.

Zhou B, Margariti A, Zeng L, Habi O, Xiao Q, Martin D, et al. Splicing of histone deacetylase 7 modulates smooth muscle cell proliferation and neointima formation through nuclear β-catenin translocation. Arterioscler Thromb Vasc Biol. 2011;31:2676–84. [DOI] [PubMed]

114.

Wang F, Liu Z, Park S, Gwag T, Lu W, Ma M, et al. Myeloid β-Catenin Deficiency Exacerbates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice. Arterioscler Thromb Vasc Biol. 2018;38:1468–78. [DOI] [PubMed] [PMC]

115.

Chen H, Xie C, Chen Q, Zhuang S. HDAC11, an emerging therapeutic target for metabolic disorders. Front Endocrinol (Lausanne). 2022;13:989305. [DOI] [PubMed] [PMC]

116.

Sosnowska B, Mazidi M, Penson P, Gluba-Brzózka A, Rysz J, Banach M. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis. 2017;265:275–82. [DOI] [PubMed]

117.

Gong H, Liu J, Xue Z, Wang W, Li C, Xu F, et al. SIRT3 attenuates coronary atherosclerosis in diabetic patients by regulating endothelial cell function. J Clin Lab Anal. 2022;36:e24586. [DOI] [PubMed] [PMC]

118.

Zierold S, Buschmann K, Gachkar S, Bochenek ML, Velmeden D, Hobohm L, et al. Brain-Derived Neurotrophic Factor Expression and Signaling in Different Perivascular Adipose Tissue Depots of Patients With Coronary Artery Disease. J Am Heart Assoc. 2021;10:e018322. [DOI] [PubMed] [PMC]

119.

Zhang Z, Salisbury D, Sallam T. Long Noncoding RNAs in Atherosclerosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2018;72:2380–90. [DOI] [PubMed] [PMC]

120.

Rezaei M, Mokhtari MJ, Bayat M, Safari A, Dianatpuor M, Tabrizi R, et al. Long non-coding RNA H19 expression and functional polymorphism rs217727 are linked to increased ischemic stroke risk. BMC Neurol. 2021;21:54. [DOI] [PubMed] [PMC]

121.

Kang C, Hu Y, Nie Y, Zhao J, Li S, Chu S, et al. Long non-coding RNA RP5-833A20.1 inhibits proliferation, metastasis and cell cycle progression by suppressing the expression of NFIA in U251 cells. Mol Med Rep. 2016;14:5288–96. [DOI] [PubMed]

122.

Hu Y, Yang J, Ma X, Chen Z, Hu Y, Zhao J, et al. A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis. J Lipid Res. 2014;55:681–97. [DOI] [PubMed] [PMC]

123.

Ballantyne MD, Pinel K, Dakin R, Vesey AT, Diver L, Mackenzie R, et al. Smooth Muscle Enriched Long Noncoding RNA (SMILR) Regulates Cell Proliferation. Circulation. 2016;133:2050–65. [DOI] [PubMed] [PMC]

124.

Li H, Pan Z, Chen Q, Yang Z, Zhang D. SMILR Aggravates the Progression of Atherosclerosis by Sponging miR-10b-3p to Regulate KLF5 Expression. Inflammation. 2020;43:1620–33. [DOI] [PubMed]

125.

Wang H, He F, Liang B, Jing Y, Zhang P, Liu W, et al. LincRNA-p21 alleviates atherosclerosis progression through regulating the miR-221/SIRT1/Pcsk9 axis. J Cell Mol Med. 2021;25:9141–53. [DOI] [PubMed] [PMC]

126.

Shi Z, Zheng Z, Lin X, Ma H. Long Noncoding RNA MALAT1 Regulates the Progression of Atherosclerosis by miR-330-5p/NF-κB Signal Pathway. J Cardiovasc Pharmacol. 2021;78:235–46. [DOI] [PubMed]

127.

Li H, Liu X, Sun N, Wang T, Zhu J, Yang S, et al. Differentially Expressed Circular Non-coding RNAs in Atherosclerotic Aortic Vessels and Their Potential Functions in Endothelial Injury. Front Cardiovasc Med. 2021;8:657544. [DOI] [PubMed] [PMC]

128.

Tong K, Tan K, Lim Y, Tien X, Wong P. CircRNA-miRNA interactions in atherogenesis. Mol Cell Biochem. 2022;477:2703–33. [DOI] [PubMed]

129.

Madrigal-Matute J, Cuervo AM, Sluimer JC. Chaperone-mediated autophagy protects against atherosclerosis. Autophagy. 2022;18:2505–7. [DOI] [PubMed] [PMC]

130.

Martinet W, Meyer GRYD. Autophagy in atherosclerosis: a cell survival and death phenomenon with therapeutic potential. Circ Res. 2009;104:304–17. [DOI] [PubMed]

131.

Salminen A, Ojala J, Kaarniranta K, Kauppinen A. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. Cell Mol Life Sci. 2012;69:2999–3013. [DOI] [PubMed] [PMC]

132.

Chattopadhyay A, Kwartler CS, Kaw K, Li Y, Kaw A, Chen J, et al. Cholesterol-Induced Phenotypic Modulation of Smooth Muscle Cells to Macrophage/Fibroblast-like Cells Is Driven by an Unfolded Protein Response. Arterioscler Thromb Vasc Biol. 2021;41:302–16. [DOI] [PubMed] [PMC]

133.

Qiao L, Ma J, Zhang Z, Sui W, Zhai C, Xu D, et al. Deficient Chaperone-Mediated Autophagy Promotes Inflammation and Atherosclerosis. Circ Res. 2021;129:1141–57. [DOI] [PubMed] [PMC]

134.

Marfella R, D’Amico M, Filippo CD, Baldi A, Siniscalchi M, Sasso FC, et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. J Am Coll Cardiol. 2006;47:2444–55. [DOI] [PubMed]

135.

Wang F, Lerman A, Herrmann J. Dysfunction of the ubiquitin-proteasome system in atherosclerotic cardiovascular disease. Am J Cardiovasc Dis. 2015;5:83–100. [PubMed] [PMC]

136.

Paul A, Chang BH, Li L, Yechoor VK, Chan L. Deficiency of adipose differentiation-related protein impairs foam cell formation and protects against atherosclerosis. Circ Res. 2008;102:1492–501. [DOI] [PubMed] [PMC]

137.

Wang B, Tang X, Yao L, Wang Y, Chen Z, Li M, et al. Disruption of USP9X in macrophages promotes foam cell formation and atherosclerosis. J Clin Invest. 2022;132:e154217. [DOI] [PubMed] [PMC]

138.

Zhang F, Xia X, Chai R, Xu R, Xu Q, Liu M, et al. Inhibition of USP14 suppresses the formation of foam cell by promoting CD36 degradation. J Cell Mol Med. 2020;24:3292–302. [DOI] [PubMed] [PMC]

139.

Wick G, Jakic B, Buszko M, Wick MC, Grundtman C. The role of heat shock proteins in atherosclerosis. Nat Rev Cardiol. 2014;11:516–29. [DOI] [PubMed]

140.

Kilic A, Mandal K. Heat shock proteins: pathogenic role in atherosclerosis and potential therapeutic implications. Autoimmune Dis. 2012;2012:502813. [DOI] [PubMed] [PMC]

141.

Xu Q, Metzler B, Jahangiri M, Mandal K. Molecular chaperones and heat shock proteins in atherosclerosis. Am J Physiol Heart Circ Physiol. 2012;302:H506–14. [DOI] [PubMed] [PMC]

142.

Lu X, Kakkar V. The role of heat shock protein (HSP) in atherosclerosis: Pathophysiology and clinical opportunities. Curr Med Chem. 2010;17:957–73. [DOI] [PubMed]

143.

Zhao Z, Zhang M, Chen L, Gong D, Xia X, Yu X, et al. Heat shock protein 70 accelerates atherosclerosis by downregulating the expression of ABCA1 and ABCG1 through the JNK/Elk-1 pathway. Biochim Biophys Acta Mol Cell Biol Lipids. 2018;1863:806–22. [DOI] [PubMed]

144.

Qi S, Yi G, Yu K, Feng C, Deng S. The Role of HSP90 Inhibitors in the Treatment of Cardiovascular Diseases. Cells. 2022;11:3444. [DOI] [PubMed] [PMC]

145.

Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121–41. [DOI] [PubMed] [PMC]

146.

Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. EXCLI J. 2021;20:301–19. [DOI] [PubMed] [PMC]

147.

Videja M, Sevostjanovs E, Upmale-Engela S, Liepinsh E, Konrade I, Dambrova M. Fasting-Mimicking Diet Reduces Trimethylamine N-Oxide Levels and Improves Serum Biochemical Parameters in Healthy Volunteers. Nutrients. 2022;14:1093. [DOI] [PubMed] [PMC]

148.

Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20:1126–67. [DOI] [PubMed] [PMC]

149.

Zhang L, Yu F, Xia J. Trimethylamine N-oxide: role in cell senescence and age-related diseases. Eur J Nutr. 2023;62:525–41. [DOI] [PubMed]

150.

Zhu X, Zhao L, Wang Y, Hu X, Zhu Y, Yang X. Dietary titanium dioxide particles (E171) promote diet-induced atherosclerosis through reprogramming gut microbiota-mediated choline metabolism in APOE^-/- mice. J Hazard Mater. 2022;436:129179. [DOI] [PubMed]

151.

Traughber CA, Iacano AJ, Neupane K, Khan MR, Opoku E, Nunn T, et al. Impavido attenuates inflammation, reduces atherosclerosis, and alters gut microbiota in hyperlipidemic mice. iScience. 2023;26:106453. [DOI] [PubMed] [PMC]

152.

Nicese MN, Bijkerk R, Zonneveld AJV, Berg BMVd, Rotmans JI. Sodium Butyrate as Key Regulator of Mitochondrial Function and Barrier Integrity of Human Glomerular Endothelial Cells. Int J Mol Sci. 2023;24:13090. [DOI] [PubMed] [PMC]

153.

Gui D, Luo W, Yan B, Ren Z, Tang Z, Liu L, et al. Effects of gut microbiota on atherosclerosis through hydrogen sulfide. Eur J Pharmacol. 2021;896:173916. [DOI] [PubMed]

154.

Zhang H, Bai Z, Zhu L, Liang Y, Fan X, Li J, et al. Hydrogen sulfide donors: Therapeutic potential in anti-atherosclerosis. Eur J Med Chem. 2020;205:112665. [DOI] [PubMed]

155.

Mani S, Untereiner A, Wu L, Wang R. Hydrogen sulfide and the pathogenesis of atherosclerosis. Antioxid Redox Signal. 2014;20:805–17. [DOI] [PubMed]

156.

Kolluru GK, Shackelford RE, Shen X, Dominic P, Kevil CG. Sulfide regulation of cardiovascular function in health and disease. Nat Rev Cardiol. 2023;20:109–25. [DOI] [PubMed] [PMC]

157.

Huang S, Li H, Ge J. A cardioprotective insight of the cystathionine γ-lyase/hydrogen sulfide pathway. Int J Cardiol Heart Vasc. 2015;7:51–7. [DOI] [PubMed] [PMC]

158.

Merz T, Wepler M, Nußbaum B, Vogt J, Calzia E, Wang R, et al. Cystathionine-γ-lyase expression is associated with mitochondrial respiration during sepsis-induced acute kidney injury in swine with atherosclerosis. Intensive Care Med Exp. 2018;6:43. [DOI] [PubMed] [PMC]

159.

Rao SP, Dobariya P, Bellamkonda H, More SS. Role of 3-Mercaptopyruvate Sulfurtransferase (3-MST) in Physiology and Disease. Antioxidants (Basel). 2023;12:603. [DOI] [PubMed] [PMC]

160.

Bittencourt MS, Cerci RJ. Statin effects on atherosclerotic plaques: regression or healing? BMC Med. 2015;13:260. [DOI] [PubMed] [PMC]

161.

Luan Y, Liu H, Luan Y, Yang Y, Yang J, Ren K. New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis. Front Pharmacol. 2022;13:863677. [DOI] [PubMed] [PMC]

162.

Neele AE, Willemsen L, Chen H, Dzobo KE, Winther MPJd. Targeting epigenetics as atherosclerosis treatment: an updated view. Curr Opin Lipidol. 2020;31:324–30. [DOI] [PubMed] [PMC]

163.

Asare Y, Campbell-James TA, Bokov Y, Yu LL, Prestel M, Bounkari OE, et al. Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability. Circ Res. 2020;127:811–23. [DOI] [PubMed]

164.

Chen L, Shang C, Wang B, Wang G, Jin Z, Yao F, et al. HDAC3 inhibitor suppresses endothelial-to-mesenchymal transition via modulating inflammatory response in atherosclerosis. Biochem Pharmacol. 2021;192:114716. [DOI] [PubMed]

165.

Lecce L, Xu Y, V’Gangula B, Chandel N, Pothula V, Caudrillier A, et al. Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype. J Clin Invest. 2021;131:e131178. [DOI] [PubMed] [PMC]

166.

Brookes RL, Crichton S, Wolfe CDA, Yi Q, Li L, Hankey GJ, et al. Sodium Valproate, a Histone Deacetylase Inhibitor, Is Associated With Reduced Stroke Risk After Previous Ischemic Stroke or Transient Ischemic Attack. Stroke. 2018;49:54–61. [DOI] [PubMed] [PMC]

167.

Fossel M, Bean J, Khera N, Kolonin MG. A Unified Model of Age-Related Cardiovascular Disease. Biology (Basel). 2022;11:1768. [DOI] [PubMed] [PMC]

168.

Shah A, Gray K, Figg N, Finigan A, Starks L, Bennett M. Defective Base Excision Repair of Oxidative DNA Damage in Vascular Smooth Muscle Cells Promotes Atherosclerosis. Circulation. 2018;138:1446–62. [DOI] [PubMed] [PMC]

169.

Fernandez ML, Thomas MS, Lemos BS, DiMarco DM, Missimer A, Melough M, et al. TA-65, A Telomerase Activator improves Cardiovascular Markers in Patients with Metabolic Syndrome. Curr Pharm Des. 2018;24:1905–11. [DOI] [PubMed]

170.

Li Y, Li S, Lin C. Effect of resveratrol and pterostilbene on aging and longevity. Biofactors. 2018;44:69–82. [DOI] [PubMed]

171.

Li J, McArdle S, Gholami A, Kimura T, Wolf D, Gerhardt T, et al. CCR5⁺T-bet⁺FoxP3⁺ Effector CD4 T Cells Drive Atherosclerosis. Circ Res. 2016;118:1540–52. [DOI] [PubMed] [PMC]

172.

Brane AC, Tollefsbol TO. Targeting Telomeres and Telomerase: Studies in Aging and Disease Utilizing CRISPR/Cas9 Technology. Cells. 2019;8:186. [DOI] [PubMed] [PMC]

173.

Xu C, Zhang X, Yang W, Gao S, Zhao N, Li P, et al. Effective prevention of atherosclerosis by non-viral delivery of CRISPR/Cas9. Nano Today. 2024;54:102097. [DOI]

174.

Jie Z, Xia H, Zhong S, Feng Q, Li S, Liang S, et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun. 2017;8:845. [DOI] [PubMed] [PMC]

175.

Constantino-Jonapa LA, Espinoza-Palacios Y, Escalona-Montaño AR, Hernández-Ruiz P, Amezcua-Guerra LM, Amedei A, et al. Contribution of Trimethylamine N-Oxide (TMAO) to Chronic Inflammatory and Degenerative Diseases. Biomedicines. 2023;11:431. [DOI] [PubMed] [PMC]

176.

Sun Y, Wang X, Liu T, Zhu X, Pan X. The multifaceted role of the SASP in atherosclerosis: from mechanisms to therapeutic opportunities. Cell Biosci. 2022;12:74. [DOI] [PubMed] [PMC]

177.

Blagosklonny MV. Paradoxes of senolytics. Aging (Albany NY). 2018;10:4289–93. [DOI] [PubMed] [PMC]

178.

Albosta MS, Grant JK, Taub P, Blumenthal RS, Martin SS, Michos ED. Inclisiran: A New Strategy for LDL-C Lowering and Prevention of Atherosclerotic Cardiovascular Disease. Vasc Health Risk Manag. 2023;19:421–31. [DOI] [PubMed] [PMC]

179.

Yurtseven E, Ural D, Baysal K, Tokgözoğlu L. An Update on the Role of PCSK9 in Atherosclerosis. J Atheroscler Thromb. 2020;27:909–18. [DOI] [PubMed] [PMC]

180.

Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med. 2017;376:41–51. [DOI] [PubMed] [PMC]

181.

Jiang F, Yang J, Zhang Y, Dong M, Wang S, Zhang Q, et al. Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets. Nat Rev Cardiol. 2014;11:413–26. [DOI] [PubMed] [PMC]

182.

Badae NM, Naggar ASE, Sayed SME. Is the cardioprotective effect of the ACE2 activator diminazene aceturate more potent than the ACE inhibitor enalapril on acute myocardial infarction in rats? Can J Physiol Pharmacol. 2019;97:638–46. [DOI] [PubMed]

183.

Wahid A, Chen W, Wang X, Tang X. High-mobility group box 1 serves as an inflammation driver of cardiovascular disease. Biomed Pharmacother. 2021;139:111555. [DOI] [PubMed]

184.

Xu H, Xiang Q, Li S, Liu Y. High serum Bhlhe40 levels are associated with subclinical atherosclerosis in patients with type 2 diabetes mellitus: A cross-sectional study. Diab Vasc Dis Res. 2023;20:14791641231169246. [DOI] [PubMed] [PMC]

185.

Zhang Y, He Y, Liu S, Deng L, Zuo Y, Huang K, et al. SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms. Am J Cardiovasc Drugs. 2023;23:641–62. [DOI] [PubMed]

186.

Posma JJN, Sluimer JC. Pleiotropic, Cellular Effects of Rivaroxaban on Autophagy Explain Atheroprotective Effects. JACC Basic Transl Sci. 2021;6:981–3. [DOI] [PubMed] [PMC]

187.

Perrotta P, Emini Veseli B, Van der Veken B, Roth L, Martinet W, De Meyer GRY. Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis. Vascul Pharmacol. 2019;112:72–8. [DOI] [PubMed]

188.

Theelen TL, Lappalainen JP, Sluimer JC, Gurzeler E, Cleutjens JP, Gijbels MJ, et al. Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice. Atherosclerosis. 2015;241:297–304. [DOI] [PubMed] [PMC]

189.

Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov. 2017;16:635–61. [DOI] [PubMed]

190.

Tikka A, Jauhiainen M. The role of ANGPTL3 in controlling lipoprotein metabolism. Endocrine. 2016;52:187–93. [DOI] [PubMed] [PMC]

191.

Carnevale R, Nocella C, Schiavon S, Cammisotto V, Cotugno M, Forte M, et al. Beneficial effects of a combination of natural product activators of autophagy on endothelial cells and platelets. Br J Pharmacol. 2021;178:2146–59. [DOI] [PubMed]

192.

Akter R, Afrose A, Rahman MR, Chowdhury R, Nirzhor SSR, Khan RI, et al. A Comprehensive Analysis into the Therapeutic Application of Natural Products as SIRT6 Modulators in Alzheimer’s Disease, Aging, Cancer, Inflammation, and Diabetes. Int J Mol Sci. 2021;22:4180. [DOI] [PubMed] [PMC]